Kala launches Eysuvis for the treatment of short-term dry eye

Eysuvis is now available for the short-term treatment of dry eye, according to a press release from Kala Pharmaceuticals.

Eysuvis uses Kala’s proprietary Ampplify mucus-penetrating particulate drug delivery technology for enhanced penetration of loteprednol etabonate into target ocular surface tissue to treat the signs and symptoms of dry eye disease. The treatment also offers a favorable tolerance and safety profile and has the potential to complement existing therapies, according to the release.

“We are delighted to announce our second product launch in 2 years, with Eysuvis now available in the United States as the first approved prescription treatment specifically indicated for the short-term treatment of dry eye,” Marc Iwicki, chairman, chairman and chief executive officer of Kala, said in the statement.

The FDA approved Eysuvis in October 2020.